JP3317901B2 - Lipid peroxide inhibitor for epilepsy and method for producing the same - Google Patents
Lipid peroxide inhibitor for epilepsy and method for producing the sameInfo
- Publication number
- JP3317901B2 JP3317901B2 JP21638598A JP21638598A JP3317901B2 JP 3317901 B2 JP3317901 B2 JP 3317901B2 JP 21638598 A JP21638598 A JP 21638598A JP 21638598 A JP21638598 A JP 21638598A JP 3317901 B2 JP3317901 B2 JP 3317901B2
- Authority
- JP
- Japan
- Prior art keywords
- epilepsy
- lipid peroxide
- producing
- water
- peroxide inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- -1 Lipid peroxide Chemical class 0.000 title claims description 46
- 206010015037 epilepsy Diseases 0.000 title claims description 41
- 239000003112 inhibitor Substances 0.000 title claims description 31
- 238000004519 manufacturing process Methods 0.000 title claims description 27
- 240000008397 Ganoderma lucidum Species 0.000 claims description 43
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- 239000000284 extract Substances 0.000 claims description 35
- 239000003960 organic solvent Substances 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 9
- 241000124879 Grus leucogeranus Species 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 description 11
- 229920001353 Dextrin Polymers 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 235000019425 dextrin Nutrition 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 150000002505 iron Chemical class 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 230000000472 traumatic effect Effects 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 210000003710 cerebral cortex Anatomy 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000009965 odorless effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 229960002911 zonisamide Drugs 0.000 description 2
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- XOBKSJJDNFUZPF-UHFFFAOYSA-N Methoxyethane Chemical compound CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 239000008239 natural water Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Description
【0001】本発明は、白鶴霊芝を用いての外傷性てん
かん等に有効な過酸化脂質抑制剤及びその製造方法に関
する。The present invention relates to a lipid peroxide inhibitor effective for traumatic epilepsy using Hakutsuru Reishi and a method for producing the same.
【0002】[0002]
【従来の技術】外傷性てんかんは活性酸素を発生させ、
大脳皮質の過酸化脂質を増加させるといわれている。こ
の過酸化脂質は膜構造の破壊など広範な膜傷害を誘導す
る他、細胞毒性などを二次的に生成する弊害がある[内
田浩二「脂質酸化物による蛋白質の変化」、井上正康編
著 活性酸素と医食同源、共立出版(1996)]。外
傷性てんかんによるこのような障害を除くためには、抗
てんかん薬による根本治療によるか或いは直接的に過酸
化脂質の生成を抑制する薬剤を投与する方法が採られて
いる。たとえば抗てんかん薬ゾニサミドについて過酸化
脂質抑制効果を検討した小松等の研究[小松等「ゾニサ
ミドの過酸化脂質抑制作用について」NEUROSCI
ENCES,May,1995,Vol.21,P63
−P66]は根本治療、即ちてんかんを治療することに
よる過酸化脂質の抑制を意図している。2. Description of the Related Art Traumatic epilepsy generates active oxygen,
It is said to increase lipid peroxide in the cerebral cortex. This lipid peroxide induces a wide range of membrane damage such as disruption of membrane structure, and has the adverse effect of secondary production of cytotoxicity [Koji Uchida, “Changes in Proteins by Lipid Oxide”, edited by Masayasu Inoue, Active Oxygen And Kyokuryu Shuppan (1996)]. In order to eliminate such disorders caused by traumatic epilepsy, a method of administering a drug which suppresses the production of lipid peroxide by radical treatment with an antiepileptic drug or directly has been adopted. For example, a study by Komatsu et al. On the study of the antiepileptic drug zonisamide on the lipid peroxide inhibitory effect [Komatsu et al. "On the lipid peroxide inhibitory effect of zonisamide" NEUROSCI
ENSES, May, 1995, Vol. 21, P63
-P66] is intended for radical treatment, i.e., suppression of lipid peroxides by treating epilepsy.
【0003】白鶴霊芝(Rhinacanthus n
asuta(L.)Kurz)は、インド南部デカン高
原の原産とされるリナカンサス属きつねのまご科に属す
る常緑小低木であり、その全草(リナカンツス草)は駆
虫、消炎、皮膚真菌に対する抗菌作用のあることが知ら
れ(原色牧野和漢薬草大図鑑、第492頁、北隆館、1
988年)、主に中国、台湾等において、また最近では
日本国においても漢方薬として用いられている。その
他、本出願人による以前の出願で、この白鶴霊芝に活性
酸素消去能があること(特開平9−143091号、活
性酸素消去能を有する組成物)および排泄促進作用があ
ること(特開平9−169662号、排泄促進剤)を開
示している。しかしながら、この白鶴霊芝乃至白鶴霊芝
の水および/または有機溶媒抽出物に過酸化脂質抑制作
用があることは知られていない。[0003] Rinacanthus n
asuta (L.) Kurz) is an evergreen shrub belonging to the linac family of the genus Linacanthus, which is native to the Deccan Plateau in southern India. (Primary Color Makino Kazoku Herb Encyclopedia, p. 492, Hokuryukan, 1
988), mainly in China, Taiwan, etc., and recently also in Japan. In addition, in a previous application filed by the present applicant, this white cranes Reishi had the ability to scavenge active oxygen (Japanese Patent Application Laid-Open No. 9-143091, a composition having the ability to scavenge active oxygen) and the effect of promoting excretion (Japanese Unexamined Patent Application Publication No. No. 9-169662, excretion enhancer). However, it is not known that the water and / or organic solvent extract of Hakutsuru Reishi or Hakutsuru Reishi has an effect of inhibiting lipid peroxide.
【0004】[0004]
【発明が解決しようとする課題】本発明者等は、外傷性
てんかんによる過酸化脂質の生成を抑制する物質につき
鋭意研究の結果、従来漢方薬、排泄促進剤および健康食
品として使用されている白鶴霊芝の水および/または有
機溶媒抽出物が有効であることを見出し、本発明を完成
させるに至った。DISCLOSURE OF THE INVENTION The present inventors have conducted intensive studies on substances that suppress the production of lipid peroxides due to traumatic epilepsy, and as a result, have found that white crane spirits, which have been used as a traditional Chinese medicine, an excretion enhancer, and a health food. The inventors have found that turf water and / or organic solvent extracts are effective, and have completed the present invention.
【0005】[0005]
【課題を解決するための手段】本発明は、白鶴霊芝の水
および/または有機溶媒抽出物を主成分とすることを特
徴とするてんかんの過酸化脂質抑制剤である。また、本
発明は、白鶴霊芝の水および/または有機溶媒抽出液を
主成分とすることを特徴とするてんかんの過酸化脂質抑
制剤である。また、本発明は、白鶴霊芝の水および/ま
たは有機溶媒抽出液を処理して得られる微粉末を主成分
とすることを特徴とするてんかんの過酸化脂質抑制剤で
ある。また、本発明は、白鶴霊芝の水および/または有
機溶媒抽出物を主成分とするてんかんの過酸化脂質抑制
剤を製造するための方法であって、白鶴霊芝を、熱水に
より抽出することを特徴とする、てんかんの過酸化脂質
抑制剤の製造方法である。また、本発明は、白鶴霊芝の
水および/または有機溶媒抽出物を主成分とするてんか
んの過酸化脂質抑制剤を製造するための方法であって、
白鶴霊芝を、エタノールにより抽出することを特徴とす
る、てんかんの過酸化脂質抑制剤の製造方法である。ま
た、本発明は、白鶴霊芝の水および/または有機溶媒抽
出物を主成分とするてんかんの過酸化脂質抑制剤を製造
するための方法であって、白鶴霊芝を、「1:1エタノ
ール水」により抽出することを特徴とする、てんかんの
過酸化脂質抑制剤の製造方法である。また、本発明は、
白鶴霊芝の水および/または有機溶媒抽出物を主成分と
するてんかんの過酸化脂質抑制剤を製造するための方法
であって、天日乾燥および/またはドラム乾燥した白鶴
霊芝を焙煎し、この焙煎された白鶴霊芝を水および/ま
たは有機溶媒で抽出することを特徴とする、てんかんの
過酸化脂質抑制剤の製造方法である。また、本発明は、
白鶴霊芝の水および/または有機溶媒抽出物を主成分と
するてんかんの過酸化脂質抑制剤を製造するための方法
であって、白鶴霊芝を粉砕機にかけて12メッシュ以下
に粉砕し、この粉砕された白鶴霊芝を水および/または
有機溶媒で抽出することを特徴とする、てんかんの過酸
化脂質抑制剤の製造方法である。DISCLOSURE OF THE INVENTION The present invention is a lipid peroxide inhibitor for epilepsy characterized by containing a water and / or organic solvent extract of Hakutsuru Reishi as a main component. Further, the present invention is a lipid peroxide inhibitor for epilepsy, characterized in that the extract contains water and / or an organic solvent extract of Hakutsuru Reishi. Further, the present invention is a lipid peroxide inhibitor for epilepsy, characterized by comprising as a main component a fine powder obtained by treating water and / or an organic solvent extract of Hakutsuru Reishi. The present invention also relates to a method for producing a lipid peroxide inhibitor for epilepsy comprising a water and / or organic solvent extract of Hakutsuru Reishi, wherein Hakutsuru Reishi is extracted with hot water. A method for producing a lipid peroxide inhibitor for epilepsy, characterized in that: The present invention also provides a method for producing a lipid peroxide inhibitor for epilepsy comprising a water and / or organic solvent extract of Hakutsuru Reishi as a main component,
A method for producing a lipid peroxide inhibitor for epilepsy, comprising extracting Hakutsuru Reishi with ethanol. The present invention also relates to a method for producing a lipid peroxide inhibitor of epilepsy comprising a water and / or organic solvent extract of Hakutsuru reishi as a main component, comprising the steps of: A method for producing a lipid peroxide inhibitor for epilepsy, characterized by extracting with water. Also, the present invention
A method for producing a lipid peroxide inhibitor for epilepsy based on a water and / or organic solvent extract of Hakutsuru Reishi, comprising roasting sun-dried and / or drum-dried Hakutsuru Reishi. A method for producing a lipid peroxide inhibitor for epilepsy, comprising extracting the roasted Hakutsuru Reishi with water and / or an organic solvent. Also, the present invention
A method for producing a lipid peroxide inhibitor for epilepsy comprising a water and / or organic solvent extract of Hakutsuru Reishi as a main component, wherein Hakutsuru Reishi is pulverized to 12 mesh or less using a pulverizer. A method for producing a lipid peroxide inhibitor for epilepsy, comprising extracting the extracted Hakutsuru Reishi with water and / or an organic solvent.
【0006】[0006]
【発明の実施の形態】本発明に使用する白鶴霊芝は、市
販されている葉、全草(地上部)あるいはこれらのもの
に根を混合したものを使用すればよい。好ましくはこれ
らのものを天日乾燥および/またはドラム乾燥し、粉砕
機にかけて20メッシュ以下、好ましくは12メッシュ
以下に粉砕して用いる。必要によりこの白鶴霊芝は、天
日乾燥および/またはドラム乾燥したものを焙煎器によ
り焙煎したものを用いてもよい。BEST MODE FOR CARRYING OUT THE INVENTION As the white cranes used in the present invention, commercially available leaves, whole plants (aboveground parts) or a mixture of these with roots may be used. Preferably, these are sun-dried and / or drum-dried and pulverized with a pulverizer to 20 mesh or less, preferably 12 mesh or less. If necessary, this Hakutsuru Reishi may be obtained by sun-dried and / or drum-dried and roasted by a roaster.
【0007】このようにして得られた白鶴霊芝を水およ
び/または有機溶媒で抽出して本発明過酸化脂質抑制剤
である抽出物を得る。[0007] The thus obtained Hakutsuru Reishi is extracted with water and / or an organic solvent to obtain an extract which is the lipid peroxide inhibitor of the present invention.
【0008】本発明において、抽出に使用する水には冷
却水、常温水および熱水が包含される。In the present invention, the water used for the extraction includes cooling water, room temperature water and hot water.
【0009】本発明において、抽出に使用する有機溶媒
としては、エタノール、メタノール、プロパノール、
1,3−ブチレングリコール等のアルコール類、ジメチ
ルエーテル、ジエチルエーテル、メチルエチルエーテル
等のエーテル類、アセトン等のケトン類、ベンゼン等の
フェノール類、ヘキサン、ヘプタン、流動パラフィン、
スクワラン等の炭化水素類、その他が挙げられ、これら
を単独でまたは2種以上を混合して使用することができ
る。In the present invention, the organic solvent used for extraction includes ethanol, methanol, propanol,
Alcohols such as 1,3-butylene glycol, ethers such as dimethyl ether, diethyl ether and methyl ethyl ether, ketones such as acetone, phenols such as benzene, hexane, heptane, liquid paraffin,
Examples thereof include hydrocarbons such as squalane and the like, and these can be used alone or as a mixture of two or more.
【0010】得られる白鶴霊芝の水および/または有機
溶媒抽出物は、無臭乃至僅かな芳香、独特のコクのある
味を帯びた透明で緑褐色乃至深い緑色の液体であり、こ
れをそのまま使用してもよいが、好ましくは濾過、遠
沈、その他の方法で精製し、さらには蒸留等の手段によ
り適度に濃縮して用いる。またこの抽出液をさらに蒸留
乾固、凍結乾燥等の手段で処理して得られる無臭乃至僅
かな芳香、独特のコクのある味を帯びた透明で緑褐色乃
至深い緑色の微粉末として用いることも可能である。The resulting water and / or organic solvent extract of Hakutsuru Reishi is a clear, green-brown to deep green liquid having an odorless or slight fragrance and a unique rich taste. Although it may be purified, it is preferably purified by filtration, centrifugation or other methods, and further suitably concentrated and used by means such as distillation. Further, this extract may be used as a transparent green-brown to deep green fine powder having an odorless or slight aroma and a unique rich taste obtained by further treatment by distillation to dryness, freeze-drying or the like. It is possible.
【0011】次に本発明の実施例および試験例を挙げて
説明するが、これらは本発明の技術的範囲を限定するも
のではない。Next, the present invention will be described with reference to examples and test examples, but these do not limit the technical scope of the present invention.
【実施例】実施例1 天日乾燥し、次いでドラム乾燥した白鶴霊芝全草(大協
物産有限会社販売、以下白鶴霊芝の購入先は同じ)1k
gを粉砕機にて粉砕し、焙煎器にて焙煎後、さらに粉砕
し、得られた粉砕物を篩にかけて12メッシュ以下に分
級して白鶴霊芝全草粉砕物約0.8kgを得た。この白
鶴霊芝全草粉砕物2.5gを熱水100mlに浸漬、濾
過してジャスミン様の僅かな芳香、独特のコクのある味
を帯びた緑褐色の透明な液状の抽出物を得た。 Example 1 Sun-dried and then drum-dried Hakutsuru Reishi whole plant (sold by Daikyo Bussan Co., Ltd .; hereafter the same place for purchasing Hakutsuru Reishi) 1k
g is crushed by a crusher, roasted in a roaster, and further crushed, and the obtained crushed material is sieved and classified to 12 mesh or less to obtain about 0.8 kg of a ground crushed white crane Reishi. Was. 2.5 g of the ground white cranes of Reishi was immersed in 100 ml of hot water and filtered to obtain a green-brown transparent liquid extract with a slight jasmine-like aroma and a unique rich taste.
【0012】実施例2 白鶴霊芝の全草粉砕物2.5gを水100mlに浸漬、
濾過して僅かな芳香、独特のコクのある味を帯びた深い
緑色の透明な液状の抽出物を得た。 Example 2 2.5 g of ground grass of Hakutsuru Reishi was immersed in 100 ml of water.
Filtration yielded a deep green, clear liquid extract with a slight aroma and a unique rich taste.
【0013】実施例3 白鶴霊芝の葉粉砕物2.5gをエタノール100mlに
浸漬、濾過して僅かな芳香、独特のコクのある味を帯び
た深い緑色の透明な液状の抽出物を得た。 Example 3 2.5 g of ground leaves of white crane Reishi was immersed in 100 ml of ethanol and filtered to obtain a deep green transparent liquid extract with a slight aroma and a unique rich taste. .
【0014】実施例4 白鶴霊芝の葉、茎および根の粉砕物2.5gを1.3−
ブチレングリコール100mlに浸漬、濾過して僅かな
芳香、独特のコクのある味を帯びた深い緑色の透明な液
状の抽出物を得た。 Example 4 1.3 g of a crushed leaf, stem and root of Hakutsuru Reishi
It was immersed in 100 ml of butylene glycol and filtered to obtain a deep green transparent liquid extract with a slight aroma and a unique rich taste.
【0015】実施例5 白鶴霊芝の葉および根の粉砕物3gを1:1エタノール
水100mlに浸漬、濾過して僅かな芳香、独特のコク
のある味を帯びた深い緑色の透明な液状の抽出物を得
た。 Example 5 3 g of ground leaves and roots of Hakutsuru Reishi were immersed in 100 ml of 1: 1 ethanol water, filtered to give a deep green transparent liquid with a slight aroma and a unique rich taste. An extract was obtained.
【0016】実施例6 白鶴霊芝葉粉砕物2.5gを熱水100mlに浸漬、濾
過して僅かな芳香、独特のコクのある味を帯びた緑褐色
の透明な液状の抽出物を得た。 Example 6 2.5 g of ground crushed white crane leaf was immersed in 100 ml of hot water and filtered to obtain a green-brown transparent liquid extract having a slight aroma and a unique rich taste. .
【0017】実施例7 エタノールの代わりにアセトンを使用する他は実施例3
と同様に処理して、僅かな芳香を有し、独特のコクのあ
る味を帯びた深い緑色の透明な液状の抽出物を得た。 Example 7 Example 3 except that acetone was used instead of ethanol.
To give a deep green transparent liquid extract with a slight aroma and a unique rich taste.
【0018】実施例8 エタノールの代わりにエーテルを使用する他は実施例3
と同様に処理して、僅かな芳香を有し、独特のコクのあ
る味を帯びた深い緑色の透明な液状の抽出物を得た。 Example 8 Example 3 except that ether is used instead of ethanol
To give a deep green transparent liquid extract with a slight aroma and a unique rich taste.
【0019】実施例9 エタノールの代わりにベンゼンを使用する他は実施例3
と同様に処理して、僅かな芳香を有し、独特のコクのあ
る味を帯びた深い緑色の透明な液状の抽出物を得た。 Example 9 Example 3 except that benzene was used instead of ethanol
To give a deep green transparent liquid extract with a slight aroma and a unique rich taste.
【0020】実施例10 天日乾燥し、次いでドラム乾燥した白鶴霊芝全草および
根1kgを粉砕機にて粉砕し、焙煎器にて焙煎後、さら
に粉砕し、得られた粉砕物を篩にかけて12メッシュ以
下に分級して白鶴霊芝全草および根の粉砕物約0.8k
gを得る他は、実施例1と同様に処理して僅かな芳香、
独特のコクのある味を帯びた緑褐色の透明な液状の抽出
物を得た。 Example 10 Sun-dried and then drum-dried whole grass and roots of Hakutsuru Reishi were crushed by a crusher, roasted by a roaster, and further crushed. It is sieved and classified to 12 mesh or less.
Except to obtain g, treat in the same manner as in Example 1 to give a slight aroma,
A green-brown transparent liquid extract with a unique rich taste was obtained.
【0021】実施例11 実施例1と同様に処理して得られた抽出物1000ml
を凍結乾燥して、僅かな芳香、独特のコクのある味を帯
びた緑褐色の微粉末約10mgを得た。 Example 11 1000 ml of extract obtained by treating in the same manner as in Example 1
Was freeze-dried to give about 10 mg of a greenish brown fine powder with a slight aroma and a unique rich taste.
【0022】実施例12 実施例2と同様に処理して得られた抽出物1000ml
を凍結乾燥して、僅かな芳香、独特のコクのある味を帯
びた緑褐色の微粉末約10mgを得た。 Example 12 1000 ml of extract obtained by treating in the same manner as in Example 2
Was freeze-dried to give about 10 mg of a greenish brown fine powder with a slight aroma and a unique rich taste.
【0023】実施例13 実施例3と同様に処理して得られた抽出物1000ml
を凍結乾燥して、僅かな芳香、独特のコクのある味を帯
びた深い緑色の微粉末約10mgを得た。 Example 13 1000 ml of extract obtained by treating in the same manner as in Example 3
Was lyophilized to give about 10 mg of a deep green fine powder with a slight aroma and a unique rich taste.
【0024】実施例14 実施例4と同様に処理して得られた抽出物1000ml
を凍結乾燥して、僅かな芳香、独特のコクのある味を帯
びた深い緑色の微粉末約10mgを得た。 Example 14 1000 ml of extract obtained by treating in the same manner as in Example 4
Was lyophilized to give about 10 mg of a deep green fine powder with a slight aroma and a unique rich taste.
【0025】試験例 ラットの大脳皮質に鉄塩を注入して外傷性てんかんモデ
ルのラットを作り、これに実施例1の方法で抽出した白
鶴霊芝全草の熱水抽出物のデキストリン倍散品を投与し
て過酸化脂質の抑制効果を検討した。過酸化脂質の抑制
効果は、過酸化脂質の代謝物であるMalonalde
hyde(MDΛ)を測定することによって判定した。試験方法 1)投与サンプル 白鶴霊芝全草熱水抽出物のデキストリン倍散品(1:
1)(丸善製薬販売) デキストリン(和光純薬販売) 2)投与方法 白鶴霊芝全草の熱水抽出物のデキストリン倍散品は8m
g/mlに、デキストリンは4mg/mlに水道水で調
製して、それぞれ自由摂取させた。対照には水道水を自
由摂取させた。 3)投与期間 鉄塩注入前20日間および鉄塩注入後10日間モデルラットの作成 Wistar系ラット(1群5〜8匹)に対する鉄塩注
入によりモデルラットを作成した。即ち、エーテル麻酔
したラットの左大脳皮質にマイクロシリンジで0.1m
ol/l FeCl3を5μl注入した。対照にはFe
Cl3の代わりにpH1.7に調整した生理食塩水を5
μl注入した。また、比較群として本発明に係る白鶴霊
芝デキストリン倍散品を投与しない水のみ投与のてんか
んモデルラット群およびサンプル基剤のみ投与のてんか
んモデルラット群をおいた。傷口を縫合した後、投与を
続けながら10日間飼育した。 4)MDA測定 モデルラットの大脳皮質を3倍量の20mmol/l
Tris−HCl(pH7.4)バッファー中でホモジ
ネートし、3,000×g、4℃で10分間遠心分離し
た上清を測定に用いた。測定にはOXIS Inter
national社のBIOXYTEC LPO−58
6を使用した。同時に補正用のタンパク質量も測定し
た。結果と考察 結果を表1に示す。 水・鉄塩投与(てんかんモデルラット)群は水・生理食
塩水投与(対照)群に比べMDA値が有意に増加した
(P<0.01)。サンプル・鉄塩投与(白鶴霊芝デキ
ストリン倍散品)群は水・鉄塩投与(てんかんモデルラ
ット)群に比べMDA値が有意に減少し(P<0.00
5)、対照とほぼ同じ値であった。水・鉄塩投与(デキ
ストリン)群は対照に対してMDAが増加しており、デ
キストリンには過酸化脂質の抑制作用がないと認められ
た。これに対してサンプル・鉄塩投与(白鶴霊芝デキス
トリン倍散品)群は、鉄塩を注入することによって増大
させたMDA値を減少させており、サンプル基剤(デキ
ストリン)に過酸化脂質の抑制作用がないので、この作
用は白鶴霊芝によるものと認められた。 Test Example A rat of a traumatic epilepsy model was prepared by injecting an iron salt into the cerebral cortex of a rat, and a dextrin doubled product of a hot water extract of the whole plant of Hakutsuru Reishi was extracted by the method of Example 1. Was administered to examine the inhibitory effect of lipid peroxide. The inhibitory effect of lipid peroxide is due to the use of Malonalde, a metabolite of lipid peroxide.
The determination was made by measuring the hydraulic (MD @). Test method 1) Administered sample Dextrin doubled product of Hakutsuru Reishi whole plant hot water extract (1:
1) (Maruzen Pharmaceutical sales) Dextrin (Wako Pure Chemicals sales) 2) Administration method Dextrin double-drinked product of hot water extract of Hakutsuru Reishi whole plant is 8m
g / ml, and dextrin was adjusted to 4 mg / ml with tap water, and each was freely ingested. Controls received tap water ad libitum. 3) Administration period Preparation of model rats 20 days before iron salt injection and 10 days after iron salt injection Model rats were prepared by injecting iron salts into Wistar rats (5 to 8 rats per group). That is, 0.1 m of the left cerebral cortex of a rat anesthetized with ether was injected with a microsyringe.
5 μl of ol / l FeCl 3 was injected. The control is Fe
5 physiological saline adjusted to pH 1.7 instead of Cl3
μl was injected. In addition, as a comparative group, an epilepsy model rat group administered only with water and an epilepsy model rat group administered only with a sample base without administration of the Hakutsuru Reishi dextrin double powder according to the present invention. After suturing the wound, the animals were bred for 10 days while the administration was continued. 4) MDA measurement The cerebral cortex of the model rat was tripled to 20 mmol / l
The supernatant was homogenized in a Tris-HCl (pH 7.4) buffer, and centrifuged at 3,000 × g at 4 ° C. for 10 minutes. OXIS Inter for measurement
National's Bioxytec LPO-58
6 was used. At the same time, the amount of protein for correction was also measured. Table 1 shows the results and discussion results. The MDA value of the group administered with water / iron salt (epilepsy model rat) was significantly increased as compared with the group administered with water / saline (control) (P <0.01). The MDA value was significantly reduced in the sample / iron salt-administered (Hakutsuru Reishi dextrin double powdered) group compared to the water / iron salt-administered (epilepsy model rat) group (P <0.00).
5) The values were almost the same as the control. The MDA was increased in the water / iron salt administration (dextrin) group as compared to the control, and it was recognized that dextrin had no inhibitory effect on lipid peroxide. On the other hand, in the sample / iron salt administration (Hakutsuru Reishi dextrin double powder) group, the MDA value increased by injecting the iron salt was reduced, and the lipid peroxide was added to the sample base (dextrin). Since there was no inhibitory effect, this effect was recognized to be due to Hakutsuru Reishi.
【0026】[0026]
【発明の効果】本発明のてんかんの過酸化脂質抑制剤
は、外傷性てんかん由来の大脳皮質の過酸化脂質の生成
を抑制する優れた作用を有しており、過酸化脂質による
膜構造の破壊など広範な膜傷害や二次的に生成する細胞
毒性などを防止することが期待できる。さらに、本発明
のてんかんの過酸化脂質抑制剤は、天然物の水および/
または有機溶媒抽出物であるから安全性が高く、長期連
用しても人体に有害な作用を及ぼさない利益がある。ま
た、本発明のてんかんの過酸化脂質抑制剤の製造方法に
よれば、このようなてんかんの過酸化脂質抑制剤を得る
ことができる。Industrial Applicability The lipid peroxide inhibitor of epilepsy of the present invention has an excellent action of suppressing the production of lipid peroxide in the cerebral cortex derived from traumatic epilepsy, and the disruption of the membrane structure by lipid peroxide. It can be expected to prevent widespread membrane damage and secondary cytotoxicity. Further, the lipid peroxide inhibitor of epilepsy of the present invention comprises natural water and / or
Or, since it is an organic solvent extract, it is highly safe and has the advantage of not causing harmful effects on the human body even if it is used for a long time. According to the method for producing a lipid peroxide inhibitor of epilepsy of the present invention, such a lipid peroxide inhibitor of epilepsy can be obtained.
───────────────────────────────────────────────────── フロントページの続き (58)調査した分野(Int.Cl.7,DB名) A61K 35/78 BIOSIS(DIALOG) CA(STN) MEDLINE(STN)──────────────────────────────────────────────────続 き Continued on the front page (58) Field surveyed (Int. Cl. 7 , DB name) A61K 35/78 BIOSIS (DIALOG) CA (STN) MEDLINE (STN)
Claims (8)
出物を主成分とすることを特徴とするてんかんの過酸化
脂質抑制剤。1. A lipid peroxide inhibitor for epilepsy, characterized by containing water and / or an organic solvent extract of Hakutsuru Reishi as a main component.
出液を主成分とすることを特徴とするてんかんの過酸化
脂質抑制剤。2. A lipid peroxide inhibitor for epilepsy, characterized by comprising a water and / or organic solvent extract of Hakutsuru Reishi as a main component.
出液を処理して得られる微粉末を主成分とすることを特
徴とするてんかんの過酸化脂質抑制剤。3. A lipid peroxide inhibitor for epilepsy, comprising a fine powder obtained by treating a water and / or organic solvent extract of Hakutsuru Reishi as a main component.
抑制剤を製造するための方法であって、白鶴霊芝を、熱
水により抽出することを特徴とする、てんかんの過酸化
脂質抑制剤の製造方法。4. A method for producing a lipid peroxide inhibitor for epilepsy according to claim 1, comprising extracting Hakutsuru reishi with hot water. Method of manufacturing the agent.
抑制剤を製造するための方法であって、白鶴霊芝を、エ
タノールにより抽出することを特徴とする、てんかんの
過酸化脂質抑制剤の製造方法。5. A method for producing a lipid peroxide inhibitor of epilepsy according to claim 1, wherein the epilepsy is extracted with ethanol. Manufacturing method.
抑制剤を製造するための方法であって、白鶴霊芝を、
「1:1エタノール水」により抽出することを特徴とす
る、てんかんの過酸化脂質抑制剤の製造方法。6. A method for producing a lipid peroxide inhibitor for epilepsy according to claim 1, comprising the steps of:
A method for producing a lipid peroxide inhibitor for epilepsy, characterized by extracting with "1: 1 aqueous ethanol".
抑制剤を製造するための方法であって、天日乾燥および
/またはドラム乾燥した白鶴霊芝を焙煎し、この焙煎さ
れた白鶴霊芝を水および/または有機溶媒で抽出するこ
とを特徴とする、てんかんの過酸化脂質抑制剤の製造方
法。7. A method for producing a lipid peroxide inhibitor for epilepsy according to claim 1, wherein the sun-dried and / or drum-dried Hakutsuru Reishi is roasted and the roasted. A method for producing a lipid peroxide inhibitor for epilepsy, comprising extracting Hakutsuru Reishi with water and / or an organic solvent.
抑制剤を製造するための方法であって、白鶴霊芝を粉砕
機にかけて12メッシュ以下に粉砕し、この粉砕された
白鶴霊芝を水および/または有機溶媒で抽出することを
特徴とする、てんかんの過酸化脂質抑制剤の製造方法。8. A method for producing the lipid peroxide inhibitor for epilepsy according to claim 1, wherein the white cranes are ground with a crusher to 12 mesh or less. A method for producing a lipid peroxide inhibitor for epilepsy, comprising extracting with water and / or an organic solvent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP21638598A JP3317901B2 (en) | 1998-06-26 | 1998-06-26 | Lipid peroxide inhibitor for epilepsy and method for producing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP21638598A JP3317901B2 (en) | 1998-06-26 | 1998-06-26 | Lipid peroxide inhibitor for epilepsy and method for producing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000016945A JP2000016945A (en) | 2000-01-18 |
| JP3317901B2 true JP3317901B2 (en) | 2002-08-26 |
Family
ID=16687748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP21638598A Expired - Fee Related JP3317901B2 (en) | 1998-06-26 | 1998-06-26 | Lipid peroxide inhibitor for epilepsy and method for producing the same |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3317901B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103030620B (en) * | 2010-02-19 | 2014-10-22 | 株式会社安露莎 | Anti-obesity agent and medicinal product, food or cosmetic with lipopexia inhibiting effect |
| JP7239208B2 (en) * | 2021-08-20 | 2023-03-14 | 株式会社アルソア慧央グループ | Method for producing aging-related IL-1β blood level elevation inhibitor for oral intake |
-
1998
- 1998-06-26 JP JP21638598A patent/JP3317901B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2000016945A (en) | 2000-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101868050B1 (en) | Fermentation method using medicinal flower and skin external composition containing fermented extract by the method | |
| JP2009132662A (en) | Glutathione production promoter | |
| KR20100042337A (en) | The composition of traditional oriental medicines for reheumatoid arthritis and the method of preparing medicine for it | |
| CN106456684A (en) | Female menopause alleviation use of composition containing composite extract of red clover and pomegranate as active ingredient | |
| JP7471393B2 (en) | Tea composition having preventive or ameliorative effects on respiratory diseases and pharmaceutical composition containing the same | |
| KR101787531B1 (en) | Composition for preventing hair loss comprising extracts of crude drug complex | |
| KR100454150B1 (en) | Anti-irritant cosmetic composition containing medical plant extracts | |
| KR101706017B1 (en) | Hepatoprotective composition comprising extracts of fruits of stauntonia hexaphylla for preventing alcoholic liver injury | |
| AU2006246923A1 (en) | System and method for promoting hair growth and improving hair and scalp health | |
| KR20180130080A (en) | Anti-inflammatory composition comprising extracts of grasses and preparing method thereof | |
| KR20180104516A (en) | Method for producing medicine of skin diseases | |
| JP3317901B2 (en) | Lipid peroxide inhibitor for epilepsy and method for producing the same | |
| KR20230081343A (en) | Hair and scalp cosmetic composition containing natural fermented extract | |
| KR101988295B1 (en) | Composition for skin moisturizing and anti-wrinkle comprising herbal medicine mixed extract as effective component | |
| KR101736716B1 (en) | Cosmetic composition for skin elasticity and anti-wrinkle comprising plants extract | |
| JP3455436B2 (en) | How to make antioxidants | |
| Nayak | A phytopharmacological review of prospective of bhrungaraj (Eclipta alba Hassk.) | |
| KR102421800B1 (en) | Composition comprising fermented extract of Halophilic microorganism | |
| KR101968891B1 (en) | Composition for treating hangover comprising extracts of fruits of stauntonia hexaphylla | |
| CN114788796A (en) | Whitening antibacterial cosmetic containing Fuding white tea extract and preparation method thereof | |
| KR100672036B1 (en) | Asthma Treatments with Honey Extract | |
| KR101773318B1 (en) | Hepatoprotective composition comprising extracts of fruits of stauntonia hexaphylla for preventing alcoholic liver injury | |
| KR102194450B1 (en) | Composition for increase of muscle function comprising extract of juniperus rigida | |
| KR102157138B1 (en) | Composition for preventing and treating arthritis comprising extract of juniperus rigida | |
| CN103751073B (en) | Compound traditional Chinese medicine extract with function of removing dandruff, and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20020529 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080614 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110614 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110614 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140614 Year of fee payment: 12 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |